Clinical Trial

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Study acronym: PACIFIC-8
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Protocol Amendment History 44 amendments
This ClinicalTrials.gov record has been amended 44 times since 2022-01-26; most recent amendment 2026-06-09.
Status change: Not Yet Recruiting → Recruiting 2022-03-14
Trial Details
NCT Number NCT05211895
Lead Sponsor AstraZeneca
Collaborators: Arcus Biosciences, Inc.
Conditions Non-Small Cell Lung Cancer
Enrollment 860 participants
Start Date 2022-02-18
Primary Completion 2028-07-12 (estimated)
Study Completion 2030-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-10